PF-Atlas › Clinical Trials › NCT05366387

Effect of Intrapulmonary Percussion Ventilation on Deposition of Inhaled Aerosols in Idiopathic Pulmonary Fibrosis

intrapulmonary percussive ventilation · Not specified

Registry ID
NCT05366387
Phase
Not specified
Status
Completed
Drug / intervention
intrapulmonary percussive ventilation
Sponsor
University Hospital, Tours
Start
2022-11-23
Enrollment
9
Locations
1

About this trial

This protocol aims to evaluate the feasibility and benefit of Intrapulmonary Percussive Ventilation (IPV) to improve deposition of inhaled radiolabelled aerosols in fibrotic lung regions of patients with Idiopathic Pulmonary Fibrosis (IPF). Phase 1 of the protocol aims to identify the highest IPV pressure that is tolerated by individual patients. Secondary endpoints explore safety of IPV in IPF patients. Phase 2 of the protocol is a crossover randomized trial where patients will inhale 99mTc-labelled DiethyleneTriamine PentaAcetate (DTPA) aerosols with or without IPV. Aerosol deposition in HRCT-defined fibrotic regions of interest (ROI) is described by Single Photon Emission Computed Tomography (SPECT).

View NCT05366387 on ClinicalTrials.gov →

Explore related

All intrapulmonary percussive ventilation trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05366387 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.